☆ 4.5 Article

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors

LUNG CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies

Antonio Passaro et al.

Summary: A proportion of lung cancer patients can benefit from immune checkpoint inhibitors (ICIs), but most patients experience disease progression during or after treatment. Immune resistance has different definitions based on clinical and biological features. Combination therapies are being developed to delay or prevent resistance to ICIs.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis G. Paz-Ares et al.

Summary: Nivolumab plus ipilimumab continues to demonstrate durable long-term efficacy in patients with advanced NSCLC, with a significant improvement in overall survival compared to chemotherapy. Immune-mediated adverse events occur early but can be managed with guideline-based treatment. Discontinuation of nivolumab plus ipilimumab due to adverse events does not impact the long-term benefits seen in all randomized patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

Karen L. Reckamp et al.

Summary: This randomized phase II trial demonstrated that the combination of ramucirumab and pembrolizumab significantly improved overall survival in patients with advanced non-small-cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy. The safety profile of this combination therapy was consistent with the known toxicities of both drugs.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

Roy S. Herbst et al.

Summary: First-line treatment with ramucirumab plus pembrolizumab shows manageable safety profile and strongest efficacy signal in tumors with high PD-L1 expression in patients with NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC

Yasuto Yoneshima et al.

Summary: The study evaluated the efficacy and safety of nanoparticle albumin-bound paclitaxel in previously treated advanced NSCLC patients, showing noninferiority in overall survival compared to docetaxel. Furthermore, nab-paclitaxel demonstrated a higher objective response rate and longer progression-free survival.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

Zowi R. Huinen et al.

Summary: Anti-angiogenic therapy has the potential to enhance antitumor immunity by inhibiting immunosuppressive features of angiogenesis. Combinations of anti-angiogenic agents and immunotherapy have shown success in clinical trials and have been approved by the FDA. The article discusses the impact of angiogenesis on antitumor immunity, the role of endothelial cells, and the progress in combining anti-angiogenic agents with immune checkpoint inhibitors.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Kabir A. Khan et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer et al.

LANCET (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst et al.

LANCET (2016)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon et al.

LANCET (2014)

添加到收藏夹

Article Oncology

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non-Small-Cell Lung Cancer

Daniel Morgensztern et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Timing of Administration of Bevacizumab Chemotherapy Affects Wound Healing After Chest Wall Port Placement

Joseph P. Erinjeri et al.

CANCER (2011)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Wound Dehiscence or Failure to Heal following Venous Access Port Placement in Patients Receiving Bevacizumab Therapy

Walter J. Zawacki et al.

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2009)

添加到收藏夹

Article Oncology

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

JP Sculier et al.

LUNG CANCER (2000)

添加到收藏夹

Article Oncology

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens

FV Fossella et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.